DelveInsight launched a new report on Adrenoleukodystrophy Pipeline Insights, 2020.
“Adrenoleukodystrophy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines.
Adrenoleukodystrophy (ALD) is a rare genetic condition that causes the buildup of very long chain fatty acids (VLCFAs) in the brain. When VLCFAs accumulate, they destroy the protective myelin sheath around nerve cells, responsible for brain function. Without the myelin sheath, the nerves can no longer relay information to and from the brain. The defective gene in ALD, commonly referred to as a genetic mutation, can cause several different but related conditions: adrenomyelopathy (AMN), Addison’s disease and — the most common and most devastating form — cerebral ALD. Cerebral ALD strikes boys between ages 4 and 10, leading to permanent disability and death usually within four to eight years. There are three distinct types of X-linked adrenoleukodystrophy: a childhood cerebral form, an adrenomyeloneuropathy type, and a form called Addison disease only.
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight
Signs and symptoms:
1. Progressive stiffness and weakness in the legs (paraparesis)
2. Experience urinary and genital tract disorders
3. Often show changes in behavior and thinking ability
4. Adrenocortical insufficiency
5. Damage to the brain and nervous system
Emerging therapies:
1. MGTA-456
2. OP 101
3. Elivaldogene autotemcel
Key pharma players involved:
1. Magenta Therapeutics, Inc.
2. Ashvattha Therapeutics
3. bluebird bio
Adrenoleukodystrophy Pipeline insights report provides an assessment of mono and combination therapies by Stage. Number of mono and combination products present in different phases has been provided in graphical as well as tabulated form.
Click here and download free sample pages of the report.
Table of contents:
1. Report Introduction
2. Adrenoleukodystrophy
3. Adrenoleukodystrophy Current Treatment Patterns
4. Adrenoleukodystrophy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Adrenoleukodystrophy Late Stage Products (Phase-III)
7. Adrenoleukodystrophy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Adrenoleukodystrophy Discontinued Products
13. Adrenoleukodystrophy Product Profiles
14. Adrenoleukodystrophy Key Companies
15. Adrenoleukodystrophy Key Products
16. Dormant and Discontinued Products
17. Adrenoleukodystrophy Unmet Needs
18. Adrenoleukodystrophy Future Perspectives
19. Adrenoleukodystrophy Analyst Review
20. Appendix
21. Report Methodology
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
